All News

The longer follow-up in the primary analysis of TRANSFORM provides confidence in the durability of patient responses to lisocabtagene maraleucel (liso-cel), said Jeremy Abramson, MD, director of the lymphoma program, Massachusetts General Hospital Cancer Center.

Ajai Chari, MD, professor of medicine, director of clinical research, Icahn School of Medicine at Mount Sinai, explains the mechanism of action of talquetamab and what method of delivery patients may prefer.

Among the conference highlights from the annual meeting of the Academy of Managed Care Pharmacy (AMCP) were an interview on chimeric antigen receptor T-cell therapies and a session on best practices for value-based contracting.

Cough suppression therapy is a type of behavioral intervention, but like other behavioral interventions, it requires significant work on the part of the patient, meaning motivation, therapy attendance, and compliance with therapy techniques.

Julia Balmaceda, a medical student at the University of Kansas, discusses the findings of a research project looking at whether racial bias in pulse oximetry was present in patients with acute hypoxemic respiratory failure.

Results from the ALPINE trial were presented Tuesday at a late-breaking session of the 64th American Society of Hematology Annual Meeting and Exposition, held in New Orleans, Louisiana.

Consolidation therapy with blinatumomab significantly improves overall survival (OS) in adult patients newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) who had no measurable residual disease (MRD negative) following initial treatment.

CMS plans to limit the number of nonstandardized Affordable Care Act (ACA) exchange plans offered by each insurer in 2024; CVS and Walgreens agree to settle on lawsuits revolving around their role in the opioid crisis; cases of COVID-19 rise during the holiday season as people meet with their families.

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $4 billion in annual costs and improvements in patient outcomes.

Abstracts from the American Epilepsy Society annual meeting show that telemedicine is capable of meeting the needs of patients with epilepsy, and that the patient portal accessibility for patients experiencing high social vulnerability index needs further research.

Third-line ponatinib is the optimal treatment option for patients with chronic myeloid leukemia in chronic phase (CML-CP) without T3151 mutation, said Elias Jabbour, MD, professor of medicine, Department of Leukemia, MD Anderson Cancer Center.

Authors of the observational cohort study developed and validated novel sex-informed prognostic and genomic scoring systems for patients with myelodysplastic syndrome (MDS).

Patients with Parkinson disease who adhered to Mediterranean (MEDI) and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets were associated with fewer patient-reported symptoms over time, in which the MIND diet showed greater reductions in symptom severity compared with MEDI.

About 10% of patients with blood cancer, especially those with B-cell lymphomas, who did not make anti-spike antibodies after vaccination experienced breakthrough COVID-19 infection, said Lee Greenberger, PhD, chief scientific officer, Leukemia and Lymphoma Society.

The PI3K cell-signaling network has been an important therapeutic target in oncology research for nearly 40 years ago, but the use of PI3K inhibitors in hematologic malignancies has come under scrutiny amid concerns about efficacy and safety.

Amgen will buy Horizon Therapeutics for $27.8 billion as the largest health care merger of 2022; high levels of 3 respiratory illness incite reassessment of domestic indoor mask guidelines; Juul Labs is reported to pay $1.7 billion over 500 settlements that claim that e-cigarette addiction level is higher than advertised.

The report is the first recorded case of acute respiratory distress syndrome (ARDS) that required venovenous extracorporeal membrane oxygenation and was complicated by spontaneous spleen rupture.

Use of direct-acting antiviral (DAA) treatment (without interferon) was shown to reduce liver and nonliver complications, as well as improve long-term overall survival among patients with chronic hepatitis C.

The recently published study may shed light on a potential connection between sleep quality and IVF success.

Results of a phase 3 study presented Sunday found efgartigimod allowed a third of patients with immune thrombocytopenia (ITP) to quickly achieve platelet levels that signal an ability to avoid sudden bleeding events.

Federico Stella, MD, University of Milan, explains why it was important to challenge the idea that the low-microbial protective diet is more beneficial than a nonrestrictive diet in patients with neutropenia.

Results from a phase 3 study of patients with acute myeloid leukemia (AML) are being presented at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana.

Results for talquetamab presented at the 64th American Society of Hematology Annual Meeting and Exposition showed that about 70% of patients with multiple myeloma had responses.

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on the advancement in precision medicine within dermatology and what role genetics, research, and immunology can have for care management going forward.

Building equitable clinical trials means being thoughtful about trial design and criteria, said Matthew J. Maurer, DSc, statistician at Mayo Clinic, director of the statistics and informatics core of the Lymphoma Epidemiology of Outcomes (LEO) cohort.

Aerobic capacity and cardiovascular risk both improve when people with systemic lupus erythematosus (SLE) exercise regularly, according to a new systematic review.

Response, progression-free survival, overall survival, time-to-next-treatment, and toxicity outcomes were evaluated among patients with advanced cutaneous squamous cell carcinoma (cSCC) who received first-line treatment with immune checkpoint inhibitors.

The ongoing multicenter open-label adaptively randomized phase 2 I-SPY2 trial is currently investigating dual immune blockade with cemiplimab plus the investigational agent REGN3767 as neoadjuvant therapy for early-stage, high-risk breast cancer, and new data were presented yesterday at the San Antonio Breast Cancer Symposium.